Obstructive sleep apnoea (OSA) is an independent risk factor for cardiovascular (CV) morbidity and mortality, however, the benefit of continuous positive airway pressure (CPAP) on CV disease is uncertain. Most randomized-controlled trials have focused on the role of CPAP in secondary prevention, however there is growing evidence of a potential benefit in early CV disease. Weight loss in combination with CPAP may be superior, but is difficult to achieve and maintain with conventional measures alone. Recent data from the SCOT-HEART trial collaborators demonstrated that in patients presenting with stable chest pain, low-attenuation plaque burden was the strongest predictor of fatal or nonfatal myocardial infarction, challenging the supremacy of current classical risk predictors for myocardial infarction, including stenosis severity. The aim of this study was to gain insight into the effect of CPAP on early atherosclerotic processes and to compare to a glucagon-like-peptide (GLP)-1-mediated weight loss regimen.